SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 37.64 |
Enterprise Value ($M) | 30.49 |
Book Value ($M) | 4.48 |
Book Value / Share | 0.12 |
Price / Book | 8.41 |
NCAV ($M) | 4.19 |
NCAV / Share | 0.11 |
Price / NCAV | 8.99 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.85 |
Return on Assets (ROA) | -1.84 |
Return on Equity (ROE) | -4.99 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 4.10 |
Current Ratio | 4.10 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 7.83 |
Assets | 8.12 |
Liabilities | 3.64 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.04 |
Operating Income | -10.97 |
Net Income | -8.81 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -9.12 |
Cash from Investing | -0.01 |
Cash from Financing | 15.12 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
21,781 | 104,104 | 20.92 | |
96,082 | 342,647 | 28.04 | |
91,502 | 198,830 | 46.02 | |
45,868 | 209,818 | 21.86 | |
(click for more detail) |
Similar Companies | |
---|---|
RMTI – Rockwell Medical, Inc. | RNAZ – TransCode Therapeutics, Inc. |
RNTX – Rein Therapeutics Inc. | RVPH – Reviva Pharmaceuticals Holdings, Inc. |
RZLT – Rezolute, Inc. |
Financial data and stock pages provided by
Fintel.io